PDC Therapeutics to attend ESMO 2022 Congress for poster presentation on RS-0139’s ongoing clinical trial

22 August 2022

PDC Therapeutics, a biotech company developing targeted Polymer-Drug Conjugate technologies that are committed to advancing therapies with no compromise, announced the acceptance of RS-0139’s poster presentation at the ESMO Congress 2022 to be held in person on 9-13 September 2022 in Paris, France.

RS-0139 is the lead candidate of RS Research, a clinical-stage biotechnology start-up harvesting the superior therapeutic index that SagittaTM platforms are ready to offer. RS Research Medical Director Dr. Gülşah Nomak will present the candidates’ ongoing Phase Ia/Ib study at ESMO Congress 2022.

Poster Title:      Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)

Date:                   12.09.2022

Poster No:           1200TiP

Presenter:           Prof. Dr. Hakan S. Orer, Medical Pharmacology, Koc University Hospital; Dr. Gülşah Nomak, Medical Director, RS Research

The poster abstract is available online at the ESMO website.

⤓ Poster


PDC Therapeutics

PDC Therapeutics is a biotech company developing targeted Polymer-Drug Conjugate technologies that aim to provide patients with an optimal therapeutic index. Cooperating with multinational pharmaceutical companies through co-development programs, PDC Therapeutics is supported by an industry-experienced board of scientific and supervisory experts around the world. PDC Therapeutics’ proprietary clinically validated drug delivery technology SagittaTM can help discover and develop smart nanomedicines for therapies with no compromise.

For detailed information:

For media inquiries: pr@pdcbio.com
For technical inquiries: medicalinformation@pdcbio.com